Pfizer and BioNTech said on Tuesday they started a clinical trial for the Omicron-specific COVID-19 vaccine.
The study will evaluate the safety, tolerability and the level of immune response of the vaccine, according to the news release.
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3